Highly Efficient Production of Menaquinone-7 from Glucose by Metabolically Engineered Escherichia coli
Quanxiu Gao,Hao Chen,Gaoyan Wang,Wei Yang,Xiaotong Zhong,Jiezheng Liu,XiaoJing Huo,Weifeng Liu,Jianzhong Huang,Yong Tao,Baixue Lin
DOI: https://doi.org/10.1021/acssynbio.0c00568
IF: 5.249
2021-03-23
ACS Synthetic Biology
Abstract:Menaquinone-7 (MK-7) possesses wide health and medical value, and the market demand for MK-7 has increased. Metabolic engineering for MK-7 production in <i>Escherichia coli</i> still remains challenging due to the characteristics of the competing quinone synthesis, and cells mainly synthesized menaquinones under anaerobic conditions. To increase the production of MK-7 in engineered <i>E. coli</i> strains under aerobic conditions, we divided the whole MK-7 biosynthetic pathway into three modules (MVA pathway, DHNA pathway, and MK-7 pathway) and systematically optimized each of them. First, by screening and enhancing Idi expression, the amounts of MK-7/DMK-7 increased significantly. Then, in the MK-7 pathway, by combinatorial overexpression of endogenous MenA and exogenous UbiE, and fine-tuning the expression of HepPPS, MenA, and UbiE, 70 μM MK-7 was achieved. Third, the DHNA synthetic pathway was enhanced, and 157 μM MK-7 was achieved. By the combinational metabolic engineering strategies and membrane engineering, an efficient metabolic engineered <i>E. coli</i> strain for MK-7 synthesis was developed, and 200 μM (129 mg/L) MK-7 was obtained in shake flask experiment, representing a 306-fold increase compared to the starting strain. In the scale-up fermentation, 2074 μM (1350 mg/L) MK-7 was achieved after 52 h fermentation with a productivity of 26 mg/L/h. This is the highest titer of MK-7 ever reported. This study offers an alternative method for MK-7 production from biorenewable feedstock (glucose) by engineered <i>E. coli</i>. The high titer of our process should make it a promising cost-effective resource for MK-7.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00568?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00568</a>.Figure S1: MK-7 concentration, glucose remaining, and acetate produced from cells at different OD<sub>600</sub> by whole-cell bioconversion of MK14; Figure S2: Growth curve of the strains MK16, MK17, and MK19 in minimal medium; Figure S3: Details of fermentation operation; Figure S4: Concentration of residual glucose in the secondary fermentation; Figure S5: Chromatography of MK-7 and byproducts by UPLC-mass spectrometry system; Table S1: Strains and plasmids applied in this research; Table S2: Primers of key genes used in this study; Table S3: The sequences of exogenous genes used in this study (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00568/suppl_file/sb0c00568_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.
biochemical research methods